Cory Rathgeber, MD
Family Medicine · Dickinson, NDNPI 1649367343
Payments from drug & device makers
Across 449 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$842
- Amgen$692
- Lilly USA, LLC$663
- Boehringer Ingelheim$567
- Pfizer$558
- Novo Nordisk$424
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,918100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $842 |
| Amgen | 47 | $692 |
| Lilly USA, LLC | 67 | $663 |
| Boehringer Ingelheim | 53 | $567 |
| Pfizer | 43 | $558 |
| Novo Nordisk | 35 | $424 |
| Lundbeck LLC | 20 | $348 |
| Astellas Pharma US Inc | 17 | $327 |
| AbbVie(2 entities) | 24 | $325 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $300 |
| Novartis | 20 | $264 |
| Abbott | 4 | $233 |
| E.r. Squibb & Sons, L.L.C. | 12 | $170 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $141 |
| Bayer | 5 | $118 |
| Medtronic | 1 | $109 |
| Exact Sciences | 6 | $92 |
| GSK | 6 | $92 |
| Sanofi-aventis U.S. LLC | 6 | $90 |
| Merck | 5 | $71 |
| Johnson & Johnson | 5 | $70 |
| Dexcom, Inc. | 4 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $41 |
| Edwards Lifesciences | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Verona Pharma, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Athena Bioscience, LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Dynavax Technologies Corporation | 2 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$392
- SYMBICORT$290
- FreeStyle Libre 2$184
- BREZTRI AEROSPHERE$142
- MINIMED 780G$109
- BREZTRI$102
How this compares
$6,918 in reported general payments places this provider in the 95th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 537 | $267,963 |
| JardianceEmpagliflozin | 291 | $179,915 |
| XareltoRivaroxaban | 156 | $105,020 |
| OzempicSemaglutide | 93 | $98,466 |
| MounjaroTirzepatide | 72 | $75,006 |
| NuplazidPimavanserin Tartrate | 11 | $58,150 |
| Dupixent SyringeDupilumab | 12 | $48,236 |
| TrulicityDulaglutide | 34 | $38,749 |
| JanuviaSitagliptin Phosphate | 31 | $32,792 |
| FarxigaDapagliflozin Propanediol | 43 | $30,450 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $30,062 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $28,813 |
| Repatha SureclickEvolocumab | 49 | $26,140 |
| Incruse ElliptaUmeclidinium Bromide | 70 | $25,770 |
| RybelsusSemaglutide | 26 | $25,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $558 | $267,963537 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $567 | $212,961357 claims |
| Novo NordiskOzempic, Rybelsus | $424 | $123,696119 claims |
| Lilly USA, LLCMounjaro, Trulicity | $663 | $113,755106 claims |
| Johnson & JohnsonXarelto | $70 | $105,020156 claims |
| GSKBreo Ellipta, Incruse Ellipta, Trelegy Ellipta, Anoro Ellipta | $92 | $83,133186 claims |
| MerckJanuvia | $71 | $32,79231 claims |
| AstraZenecaFarxiga | $842 | $30,45043 claims |
| Astellas Pharma US IncMyrbetriq | $327 | $19,14770 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $28 | $18,56712 claims |
| AbbVieLinzess | $325 | $11,51920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Dickinson
- Swarna YadlapalliFargo$2.9M
- Joel SchockFargo$1.2M
- Hoadley HarrisFargo$830K
- Richard VetterWest Fargo$294K
- Thomas ThorsonMandan$241K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Spencer BerryFargo$81K
- Eric JohnsonGrand Forks$52K
- Stuart TopleyFargo$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.